Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/01/2022* -- Results Q3 2022 -- 1.11 --
11/01/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 0.84 0.89 -5.69%
08/04/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 0.30 0.59 -49.25%
05/04/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/11/2022 -- Results Q4 2021 0.04 0.88 -95.48%
02/11/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/01/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since 7.89%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
URL https://www.neurocrine.com
Investor Relations URL https://neurocrine.gcs-web.com/
HQ State/Province California
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 01, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Dec. 29, 1995

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market --
Yield to Sector --
Yield to Industry --
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date Dec. 29, 1995
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
153.2%
-31.59%
100.5%
-7.96%
50.53%
-10.83%
-11.14%
21.52%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.61%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
29.08%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-38.08%
-44.57%
-56.37%
48.58%
-52.96%
5.47%
10.67%
-77.09%
23.84%
-61.17%
-88.94%
-77.05%
-79.57%
12.53%
-8.16%
83.59%
-10.22%
As of September 23, 2022.

Profile

Edit
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
URL https://www.neurocrine.com
Investor Relations URL https://neurocrine.gcs-web.com/
HQ State/Province California
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 01, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Dec. 29, 1995

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
FBT 48.15M USD 3.81%
CMIDX 34.00M USD 2.58%
ATHGX 85.51M USD 1.80%
BASAX 33.88M USD 1.70%
JFNSX 63.86M USD 1.55%
JGMCX 105.70M USD 1.42%
XBI 73.29M USD 1.09%
IJK 67.31M USD 1.06%
IBB 75.15M USD 1.00%
VISGX 150.36M USD 0.52%
VBK 150.36M USD 0.52%
IJH 288.55M USD 0.50%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NBIX Tweets